Hospital
Ohiohealth Corporation
Ohiohealth Corporation was paid $214.99M by Medicaid between Jan 2018 and Dec 2024, across 511 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoOHIOHEALTH CORPORATION
COLUMBUS, OH 43215
COLUMBUS, OH 43215
33aNPI1255377149assigned 06/21/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$214.99M
24GClaims4,231,106
24DCodes billed511
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#3 of 101
Median peer was paid$22.32M
This provider vs. median9.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BROWNING, MICHAEL controls 15+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 390,415 | $17.56M | |
| 2019 | 416,650 | $18.88M | |
| 2020 | 321,516 | $19.66M | |
| 2021 | 422,824 | $22.40M | |
| 2022 | 473,675 | $23.31M | |
| 2023 | 1,304,190 | $64.62M | |
| 2024incomplete | 901,836 | $48.57M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 257,668 | 234,632 | $39.33M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 177,333 | 157,992 | $33.27M |
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 85,577 | 65,292 | $28.81M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.6% | 77,068 | 67,145 | $16.45M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.2% | 75,605 | 69,418 | $9.06M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.5% | 27,828 | 23,644 | $7.44M |
| J2350 | Injection, ocrelizumab, 1 mg | 3.1% | 311 | 258 | $6.62M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.9% | 19,536 | 16,192 | $6.13M |
| G0378 | Hospital observation service, per hour | 2.4% | 61,415 | 26,656 | $5.07M |
| J9271 | Injection, pembrolizumab, 1 mg | 2.1% | 522 | 345 | $4.46M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.4% | 12,772 | 10,431 | $3.02M |
| J2323 | Injection, natalizumab, 1 mg | 1.3% | 574 | 499 | $2.90M |
499 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 16,980 | $2.56M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 8,322 | $2.42M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 10,307 | $2.33M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.0% | 8,628 | $2.21M |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 15,989 | $2.14M |
| 93976 | <1% | 7,230 | $1.12M | |
| 27447 | <1% | 449 | $1.04M | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 107,141 | $1.04M |
| 70496 | <1% | 3,253 | $1.04M | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 4,087 | $894K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 7,042 | $883K |
| 70498 | <1% | 5,695 | $802K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,790 | $781K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 119,529 | $731K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 86,040 | $715K |
| 59025 | Fetal non-stress test | <1% | 4,189 | $697K |
| 47562 | <1% | 200 | $629K | |
| 80053 | Comprehensive metabolic panel | <1% | 65,284 | $624K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 5,393 | $623K |
| 96415 | <1% | 2,299 | $608K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,228 | $571K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,271 | $527K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,469 | $526K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 2,820 | $502K |
| 62323 | <1% | 1,007 | $458K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 11,889 | $457K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 26,237 | $452K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 64,479 | $446K |
| 70491 | <1% | 1,419 | $437K | |
| 0240U | <1% | 3,185 | $432K | |
| 82805 | <1% | 13,206 | $423K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 975 | $417K |
| 36415 | Collection of venous blood by venipuncture | <1% | 260,171 | $417K |
| 20680 | <1% | 316 | $416K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,306 | $409K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 36,508 | $405K |
| 71045 | Radiologic examination, chest; single view | <1% | 62,807 | $402K |
| 27130 | <1% | 106 | $400K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,365 | $398K |
| 84484 | <1% | 56,020 | $364K | |
| 74174 | <1% | 4,387 | $346K | |
| 83605 | <1% | 48,485 | $339K | |
| 29827 | <1% | 145 | $318K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,842 | $317K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,420 | $316K |
| 76642 | <1% | 2,024 | $299K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 87,143 | $295K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,312 | $294K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,196 | $294K |
| 64415 | <1% | 759 | $290K | |
| 10060 | <1% | 1,676 | $281K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 204 | $277K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,182 | $275K |
| 96367 | <1% | 3,478 | $269K | |
| 93458 | <1% | 238 | $265K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 256,646 | $263K |
| 93971 | <1% | 3,188 | $255K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 15,185 | $251K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 442 | $251K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 906 | $238K |
| 93970 | <1% | 1,397 | $237K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,347 | $229K |
| 12001 | <1% | 1,372 | $227K | |
| 93922 | <1% | 2,623 | $223K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,903 | $217K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,299 | $206K |
| 64447 | <1% | 601 | $205K | |
| 86900 | <1% | 8,759 | $197K | |
| 93925 | <1% | 1,558 | $196K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,482 | $195K |
| 11045 | <1% | 492 | $186K | |
| 96376 | <1% | 15,233 | $184K | |
| 75574 | <1% | 668 | $181K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 948 | $172K |
| 72131 | <1% | 2,805 | $171K | |
| 58661 | <1% | 71 | $171K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,948 | $165K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 803 | $161K |
| J3490 | Unclassified drugs | <1% | 26,100 | $161K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 44,704 | $156K |
| 71250 | <1% | 2,076 | $155K | |
| 72141 | <1% | 868 | $151K | |
| 72197 | <1% | 514 | $149K | |
| 73221 | <1% | 611 | $148K | |
| 12011 | <1% | 846 | $145K | |
| 70486 | <1% | 2,732 | $140K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 574 | $137K |
| 72100 | <1% | 4,637 | $128K | |
| 73130 | <1% | 6,474 | $124K | |
| 71271 | <1% | 634 | $124K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,126 | $119K |
| 93017 | <1% | 1,280 | $118K | |
| 73560 | <1% | 7,575 | $116K | |
| 19083 | <1% | 127 | $112K | |
| 80320 | <1% | 6,160 | $110K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 3,269 | $109K |
| 97116 | <1% | 2,885 | $107K | |
| 29881 | <1% | 79 | $105K | |
| 74183 | <1% | 372 | $104K | |
| 84703 | <1% | 80,182 | $102K | |
| 73030 | <1% | 5,263 | $100K | |
| 52356 | <1% | 59 | $99K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 65,583 | $99K |
| 64450 | <1% | 312 | $98K | |
| 70487 | <1% | 308 | $96K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,005 | $95K |
| 76536 | <1% | 723 | $92K | |
| 12002 | <1% | 646 | $92K | |
| 76801 | <1% | 3,297 | $91K | |
| 64721 | <1% | 71 | $91K | |
| 73700 | <1% | 728 | $91K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,271 | $87K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 672 | $86K |
| 86850 | <1% | 8,496 | $86K | |
| 94660 | <1% | 1,004 | $80K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,724 | $80K |
| 83880 | <1% | 11,899 | $80K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 345 | $79K |
| 94060 | <1% | 648 | $79K | |
| 72128 | <1% | 1,712 | $77K | |
| 81001 | <1% | 111,673 | $77K | |
| 80047 | <1% | 24,750 | $76K | |
| 88307 | <1% | 653 | $74K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,223 | $74K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,285 | $73K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,714 | $72K |
| 87506 | <1% | 556 | $72K | |
| 82077 | <1% | 15,669 | $71K | |
| 73630 | <1% | 6,333 | $70K | |
| 90715 | <1% | 3,613 | $69K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 116 | $69K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 20,525 | $69K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 10,906 | $68K |
| 76820 | <1% | 701 | $67K | |
| 76821 | <1% | 680 | $67K | |
| 36591 | <1% | 1,775 | $66K | |
| 97166 | <1% | 1,620 | $66K | |
| 97162 | <1% | 1,950 | $64K | |
| 29824 | <1% | 237 | $63K | |
| 80051 | <1% | 29,162 | $62K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 57 | $61K |
| 29826 | <1% | 210 | $61K | |
| 82248 | <1% | 41,578 | $61K | |
| 72050 | <1% | 1,442 | $61K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 815 | $59K |
| 29879 | <1% | 57 | $58K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,235 | $57K |
| 72193 | <1% | 191 | $57K | |
| 58558 | <1% | 33 | $57K | |
| 29581 | <1% | 399 | $55K | |
| 85027 | <1% | 20,067 | $55K | |
| 83690 | <1% | 41,025 | $55K | |
| 73610 | <1% | 5,107 | $54K | |
| 97161 | <1% | 1,093 | $53K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 10,985 | $52K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 65,452 | $52K |
| 82330 | <1% | 30,472 | $52K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,968 | $51K |
| 74018 | <1% | 2,479 | $50K | |
| 29823 | <1% | 214 | $50K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,605 | $49K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 11,809 | $49K |
| 73502 | <1% | 2,897 | $49K | |
| 72040 | <1% | 1,046 | $48K | |
| 97165 | <1% | 773 | $45K | |
| 83050 | <1% | 12,240 | $44K | |
| 85610 | <1% | 14,221 | $44K | |
| 73110 | <1% | 3,166 | $44K | |
| 81003 | <1% | 40,992 | $44K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 55,689 | $44K |
| 20985 | <1% | 276 | $42K | |
| 96368 | <1% | 1,152 | $41K | |
| 77062 | <1% | 861 | $41K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 19,981 | $41K |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | <1% | 45 | $41K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 16,692 | $41K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 52,796 | $39K |
| 76770 | <1% | 223 | $39K | |
| 96402 | <1% | 551 | $39K | |
| 93880 | <1% | 485 | $39K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 10,905 | $38K |
| 87081 | <1% | 15,239 | $38K | |
| 72072 | <1% | 1,256 | $38K | |
| 72192 | <1% | 439 | $37K | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 3,688 | $37K |
| 99152 | <1% | 993 | $35K | |
| 93296 | <1% | 1,646 | $33K | |
| 94729 | <1% | 715 | $32K | |
| 77061 | <1% | 693 | $32K | |
| 81025 | <1% | 15,624 | $32K | |
| 86901 | <1% | 8,903 | $30K | |
| 77080 | <1% | 330 | $29K | |
| 86923 | <1% | 869 | $29K | |
| 72146 | <1% | 235 | $29K | |
| 96417 | <1% | 1,424 | $29K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,760 | $28K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 8,699 | $28K |
| 82803 | <1% | 13,328 | $27K | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 413 | $27K |
| 93308 | <1% | 86 | $27K | |
| 82375 | <1% | 12,274 | $26K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 671 | $26K |
| 76981 | <1% | 338 | $26K | |
| 72110 | <1% | 318 | $26K | |
| 73562 | <1% | 311 | $26K | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 299 | $25K |
| 82947 | <1% | 71,014 | $24K | |
| 88341 | <1% | 411 | $24K | |
| 87040 | <1% | 2,456 | $24K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 27 | $24K |
| 85379 | <1% | 6,585 | $24K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,937 | $23K |
| J2704 | Injection, propofol, 10 mg | <1% | 17,440 | $23K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 12,684 | $22K |
| 84702 | <1% | 7,434 | $22K | |
| 83735 | <1% | 9,404 | $22K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 29 | $22K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 19,889 | $21K |
| 73080 | <1% | 1,815 | $21K | |
| 94726 | <1% | 364 | $21K | |
| 96416 | <1% | 242 | $21K | |
| 97163 | <1% | 551 | $20K | |
| J1815 | Injection, insulin, per 5 units | <1% | 5,364 | $20K |
| 82150 | <1% | 13,258 | $20K | |
| 87077 | <1% | 4,747 | $20K | |
| 76942 | <1% | 1,076 | $20K | |
| 82565 | <1% | 52,119 | $20K | |
| 73590 | <1% | 2,015 | $20K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 21,942 | $19K |
| 88304 | <1% | 1,025 | $19K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 645 | $18K |
| 86140 | <1% | 2,857 | $18K | |
| 92523 | <1% | 1,074 | $18K | |
| 87070 | <1% | 2,214 | $17K | |
| 94727 | <1% | 293 | $17K | |
| 12013 | <1% | 123 | $17K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 416 | $17K |
| 23472 | <1% | 14 | $16K | |
| 80076 | <1% | 7,480 | $15K | |
| 74178 | <1% | 48 | $15K | |
| 72120 | <1% | 218 | $15K | |
| 93990 | <1% | 291 | $15K | |
| 71101 | <1% | 1,284 | $15K | |
| 82977 | <1% | 14,610 | $14K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 145 | $14K |
| 84520 | <1% | 44,277 | $14K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15,964 | $14K |
| 36416 | <1% | 2,377 | $13K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 200 | $13K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 98 | $13K |
| 85730 | <1% | 3,839 | $13K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 12,180 | $13K |
| 87186 | <1% | 4,254 | $13K | |
| 82607 | <1% | 1,388 | $13K | |
| 76870 | <1% | 743 | $13K | |
| 72070 | <1% | 357 | $12K | |
| 77066 | Tomosynthesis, mammo | <1% | 937 | $12K |
| 77065 | Tomosynthesis, mammo | <1% | 797 | $12K |
| 82728 | <1% | 1,503 | $12K | |
| 77336 | <1% | 143 | $12K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 851 | $12K |
| 73090 | <1% | 1,253 | $11K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 11,490 | $11K |
| 73701 | <1% | 36 | $11K | |
| 87210 | <1% | 3,053 | $11K | |
| 31500 | <1% | 37 | $11K | |
| 29125 | <1% | 1,034 | $10K | |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | <1% | 800 | $10K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,416 | $10K |
| 88173 | <1% | 209 | $10K | |
| 76377 | <1% | 907 | $9K | |
| 87154 | <1% | 70 | $9K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,041 | $9K |
| 84132 | <1% | 32,102 | $9K | |
| 72170 | <1% | 1,008 | $9K | |
| 73552 | <1% | 977 | $9K | |
| 97167 | <1% | 121 | $9K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,731 | $9K |
| 92950 | <1% | 46 | $8K | |
| 84295 | <1% | 31,417 | $8K | |
| 80143 | <1% | 2,036 | $8K | |
| 82040 | <1% | 13,859 | $8K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 518 | $8K |
| 87205 | <1% | 2,562 | $8K | |
| 73200 | <1% | 80 | $8K | |
| 85007 | <1% | 2,188 | $8K | |
| 93356 | <1% | 144 | $8K | |
| 72158 | <1% | 35 | $8K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 732 | $8K |
| 85018 | <1% | 14,515 | $8K | |
| J3372 | Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg | <1% | 997 | $8K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 13,192 | $7K |
| 84100 | <1% | 3,592 | $7K | |
| 73060 | <1% | 837 | $7K | |
| 83540 | <1% | 1,480 | $7K | |
| 94010 | <1% | 53 | $7K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,615 | $7K |
| 80179 | <1% | 1,971 | $7K | |
| 82746 | <1% | 1,297 | $7K | |
| 29515 | <1% | 367 | $7K | |
| 76882 | <1% | 50 | $7K | |
| 80069 | <1% | 1,258 | $7K | |
| 87075 | <1% | 1,330 | $7K | |
| 85014 | <1% | 7,681 | $7K | |
| 82435 | <1% | 20,882 | $6K | |
| C1769 | Guide wire | <1% | 1,188 | $6K |
| 85652 | <1% | 2,829 | $6K | |
| 80061 | Lipid panel | <1% | 1,107 | $6K |
| 72156 | <1% | 52 | $6K | |
| P9045 | Infusion, albumin (human), 5%, 250 ml | <1% | 29 | $6K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 8,493 | $6K |
| 88172 | <1% | 138 | $6K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 20 | $6K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,011 | $5K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 2,677 | $5K |
| 83550 | <1% | 1,466 | $5K | |
| 73201 | <1% | 18 | $5K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,021 | $5K |
| 84439 | <1% | 1,126 | $5K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,878 | $5K |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 1,478 | $5K |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 21 | $5K |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 518 | $4K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 14,920 | $4K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,506 | $4K |
| 84460 | <1% | 13,546 | $4K | |
| 84450 | <1% | 13,473 | $4K | |
| 51701 | <1% | 481 | $4K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 953 | $4K |
| 84155 | <1% | 13,271 | $4K | |
| 82247 | <1% | 13,094 | $4K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 130 | $4K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,919 | $4K |
| 74022 | <1% | 325 | $4K | |
| 97802 | <1% | 35 | $4K | |
| 84075 | <1% | 13,150 | $4K | |
| 86703 | <1% | 664 | $4K | |
| 87807 | <1% | 829 | $4K | |
| 80329 | <1% | 272 | $4K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 692 | $4K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,463 | $4K |
| 77002 | <1% | 31 | $4K | |
| 88342 | <1% | 720 | $4K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,832 | $4K |
| 82010 | <1% | 1,574 | $3K | |
| 87653 | <1% | 424 | $3K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,968 | $3K |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 1,117 | $3K |
| 76937 | <1% | 163 | $3K | |
| 95972 | <1% | 17 | $3K | |
| 63685 | <1% | 16 | $3K | |
| 15853 | <1% | 473 | $3K | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 255 | $3K |
| 87147 | <1% | 1,039 | $3K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 723 | $3K |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 272 | $3K |
| 93325 | <1% | 38 | $3K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,019 | $3K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 890 | $3K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 5,122 | $3K |
| 76775 | <1% | 18 | $3K | |
| 74280 | <1% | 12 | $3K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,598 | $3K |
| 87529 | <1% | 300 | $3K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,840 | $3K |
| 82550 | <1% | 1,219 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,362 | $2K |
| 86308 | <1% | 654 | $2K | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 2,217 | $2K |
| 83615 | <1% | 1,221 | $2K | |
| 78306 | <1% | 13 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,668 | $2K |
| 86803 | <1% | 532 | $2K | |
| 87340 | <1% | 678 | $2K | |
| 16020 | <1% | 34 | $2K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 68 | $2K |
| 86870 | <1% | 47 | $2K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,077 | $2K |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 1,039 | $2K |
| 86780 | <1% | 545 | $2K | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 613 | $2K |
| 72220 | <1% | 124 | $2K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 816 | $2K |
| 80177 | <1% | 412 | $2K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,534 | $2K |
| 84134 | <1% | 80 | $2K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,876 | $2K |
| 69209 | <1% | 357 | $2K | |
| 82570 | <1% | 820 | $2K | |
| 96523 | <1% | 22 | $1K | |
| C8908 | Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral | <1% | 16 | $1K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,468 | $1K |
| 88300 | <1% | 170 | $1K | |
| 87206 | <1% | 133 | $1K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 1,113 | $1K |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 275 | $1K |
| 88302 | <1% | 45 | $1K | |
| 82140 | <1% | 523 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 806 | $1K |
| 87102 | <1% | 69 | $1K | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 815 | $1K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 870 | $1K |
| 84550 | <1% | 965 | $1K | |
| 86592 | <1% | 545 | $1K | |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | <1% | 15 | $1K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,262 | $1K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 804 | $1K |
| 73522 | <1% | 59 | $1K | |
| 80074 | <1% | 150 | $1K | |
| 84156 | <1% | 750 | $1K | |
| 85384 | <1% | 514 | $1K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 46 | $1K |
| 87176 | <1% | 467 | $1K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 3,167 | $1K |
| 93978 | <1% | 14 | $999.54 | |
| 92610 | <1% | 64 | $915.69 | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 83 | $884.22 |
| J0703 | Injection, cefepime hydrochloride (b braun), not therapeutically equivalent to maxipime, 500 mg | <1% | 153 | $867.26 |
| 87116 | <1% | 45 | $864.00 | |
| 93298 | <1% | 160 | $846.53 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 926 | $796.60 |
| 80164 | <1% | 312 | $773.91 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,022 | $768.24 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 748 | $766.27 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 712 | $748.85 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 8,339 | $734.40 |
| 96401 | <1% | 91 | $726.31 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 1,872 | $724.98 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 914 | $715.08 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,448 | $699.92 |
| 87420 | <1% | 186 | $656.63 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 621 | $588.06 |
| 85045 | <1% | 361 | $532.41 | |
| C1729 | Catheter, drainage | <1% | 178 | $512.10 |
| 82784 | <1% | 512 | $504.39 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 450 | $494.43 |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 77 | $490.17 |
| 73020 | <1% | 69 | $480.84 | |
| 99195 | <1% | 12 | $456.20 | |
| 84145 | <1% | 61 | $453.92 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 520 | $443.29 |
| 73000 | <1% | 42 | $431.17 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 858 | $429.35 |
| J0612 | Injection, calcium gluconate, not otherwise specified, 10 mg | <1% | 338 | $410.86 |
| 73600 | <1% | 16 | $400.91 | |
| 87449 | <1% | 56 | $386.82 | |
| 29105 | <1% | 30 | $384.99 | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 32 | $352.61 |
| 73120 | <1% | 20 | $351.71 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 172 | $346.81 |
| 83521 | <1% | 12 | $316.07 | |
| 90686 | <1% | 23 | $308.05 | |
| 86880 | <1% | 13 | $307.77 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 24 | $300.37 |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 33 | $297.03 |
| 73100 | <1% | 18 | $289.53 | |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | <1% | 240 | $289.22 |
| 70360 | <1% | 49 | $269.57 | |
| 86706 | <1% | 49 | $261.45 | |
| 72020 | <1% | 57 | $248.22 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 13 | $238.07 |
| J1805 | Injection, esmolol hydrochloride, 10 mg | <1% | 355 | $236.88 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 205 | $231.33 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 63 | $175.36 |
| 87641 | <1% | 14 | $164.86 | |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | <1% | 34 | $162.10 |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 120 | $161.43 |
| 86334 | <1% | 16 | $158.71 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 41 | $147.86 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 207 | $145.50 |
| 84165 | <1% | 17 | $144.56 | |
| 36410 | <1% | 13 | $141.07 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 324 | $131.40 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 228 | $130.79 |
| 81002 | <1% | 89 | $124.20 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 48 | $108.30 |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 568 | $93.15 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 442 | $81.29 |
| 82310 | <1% | 29 | $74.78 | |
| 84153 | <1% | 12 | $59.82 | |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | <1% | 22 | $51.12 |
| 96411 | <1% | 497 | $40.28 | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 489 | $26.55 |
| J0173 | Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg | <1% | 17 | $16.40 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 169 | $12.16 |
| 89051 | <1% | 14 | $11.73 | |
| J3590 | Unclassified biologics | 0% | 21 | $0.00 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 70 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 162 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 21 | $0.00 |
| 88177 | 0% | 23 | $0.00 | |
| 99459 | 0% | 27 | $0.00 | |
| A4648 | Tissue marker, implantable, any type, each | 0% | 17 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 226 | $0.00 |
| 82365 | 0% | 19 | $0.00 | |
| C8937 | Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure) | 0% | 16 | $0.00 |
| 87076 | 0% | 14 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 29 | $0.00 |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBROWNING, MICHAEL (CFO, OHIOHEALTH)
Parent organizationOHIO HEALTH CORPORATION
| Provider | Location | Paid |
|---|---|---|
| Ohiohealth Corporation | Columbus, OH | $76.95M |
| Ohiohealth Corporation | Columbus, OH | $72.29M |
| Ohiohealth Corporation | Columbus, OH | $44.08M |
| Medcentral Health System | Mansfield, OH | $36.92M |
| Marion General Hospital, INC. | Marion, OH | $36.47M |
| Sheltering Arms Hospital Foundation, INC. | Athens, OH | $26.88M |
| Ohiohealth Berger Hospital LLC | Circleville, OH | $16.38M |
| Ohiohealth Corporation | Dublin, OH | $11.81M |
| Grady Memorial Hospital | Delaware, OH | $9.51M |
| Hardin Memorial Hospital | Kenton, OH | $7.27M |
| Medcentral Health System | Mansfield, OH | $3.13M |
| Madison Family Health Corporation | London, OH | $1.03M |
| Marion General Hospital, INC. | Marion, OH | $683K |
| Medcentral Health System | Mansfield, OH | $477K |
| Sheltering Arms Hospital Foundation | Athens, OH | $435K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.